Research programme: infectious disease vaccines - Affinivax

Drug Profile

Research programme: infectious disease vaccines - Affinivax

Latest Information Update: 03 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affinivax
  • Class Bacterial vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Pneumococcal infections
  • Research Nosocomial infections

Most Recent Events

  • 28 Feb 2017 Pneumococcal vaccines licensed to Astellas Pharma worldwide for the treatment of Pneumococcal infections
  • 05 Feb 2016 Affinivax announces intention to submit IND to US FDA for Pneumococcal vaccine
  • 26 Oct 2015 Affinivax and Nosocomial Vaccine Corporation agree to co-develop Bacterial vaccines in USA for Nosocomial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top